Nalbuphine vs Dexmedetomidine analgesia for postoperative pain in endoscopic sinus surgery

Summaries 3 min 371

Font Size

Created On: 02/09/2023

A randomized controlled trial aimed to assess the efficacy of Nalbuphine and Dexmedetomidine in lowering opioid utilization and post-surgical pain among patients undergoing endoscopic sinus surgery (ESS).

See All

Key take away

In patients undergoing endoscopic sinus surgery, both Nalbuphine and Dexmedetomidine can effectively minimize post-operative pain and opioid usage when used as pre-emptive analgesics. But, Dexmedetomidine may be a more potent analgesic when compared to Nalbuphine.

Background

Method

A total of ninety patients were selected in a random manner and administered Nalbuphine, Dexmedetomidine, or a placebo prior to the induction of anesthesia. Throughout the postoperative period, pain levels, opioid consumption, and any potential adverse effects were closely observed and recorded.

Result

Both Nalbuphine and Dexmedetomidine exhibited remarkable effectiveness in decreasing post-operative pain levels and minimizing opioid consumption when compared to the placebo. Dexmedetomidine was more successful than Nalbuphine in alleviating pain, and patients who received

Dexmedetomidine reported fewer instances of nausea and vomiting in the initial days following the surgery. However, there were no vital differences in the occurrence of sedation or respiratory depression among the groups.

Conclusion

Utilizing Nalbuphine and Dexmedetomidine as preventive analgesia presents a promising approach for pain alleviation in ESS. Dexmedetomidine, with its superior analgesic impact and lower occurrence of nausea and vomiting, emerges as a potentially preferable choice. These discoveries have the potential to improve pain management and patient satisfaction in the aftermath of ESS procedures.